AstraZeneca Global Research and Development (China) Co., Ltd. is a subsidiary of AstraZeneca, a leading global biopharmaceutical company. Founded in April 2021 and located in Shanghai, the company is a research and experimental development-oriented enterprise. The company focuses on collaborative research, talent cultivation, and sustainable innovation, and is committed to promoting the development of China's biomedical industry and global health outcomes.

Tags

Other Diseases

Endocrinology and Metabolic Disease

Neoplasms

Small molecule drug

Monoclonal antibody

Bispecific antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	15
Neoplasms	14
Immune System Diseases	10
Hemic and Lymphatic Diseases	9
Nervous System Diseases	6
Infectious Diseases	5

Top 5 Drug Type	Count

Small molecule drug	8
Monoclonal antibody	7
Bispecific antibody	5
ASO	2
Antibody drug conjugate (ADC)	2

Top 5 Target	Count

C5(Complement C5)	2
TTR(Transthyretin)	2
ETA x SGLT2	1
GLP-1R(Glucagon-like peptide 1 receptor)	1
ALDOS(Cytochrome P450 11B2)	1

Drugs associated with AstraZeneca Global R&D (China) Co., Ltd.

Eplontersen

Target

TTR

Mechanism

TTR inhibitors

Active Org.

AstraZeneca PLC [+4]

Originator Org.

Ionis Pharmaceuticals, Inc.

Active Indication

Transthyretin-related (ATTR) familial amyloid polyneuropathy [+2]

Inactive Indication

Transthyretin cardiac amyloidosis

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date21 Dec 2023

Capivasertib

Target

Akt-1 x Akt-2 x Akt-3

Mechanism

Akt-1 inhibitors [+2]

Active Org.

AstraZeneca Pharmaceuticals LP [+12]

Originator Org.

AstraZeneca PLC

Active Indication

ER-positive/HER2-negative Breast Cancer [+21]

Inactive Indication

Advanced cancer [+6]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date16 Nov 2023

Tremelimumab

Target

CTLA4

Mechanism

CTLA4 inhibitors

Active Org.

AstraZeneca PLC [+12]

Originator Org.

AstraZeneca AB [+1]

Active Indication

Hepatocellular Carcinoma [+59]

Inactive Indication

Advanced cancer [+50]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date21 Oct 2022

Clinical Trials associated with AstraZeneca Global R&D (China) Co., Ltd.

CTR20243136 / RecruitingPhase 1/2

一项评价AZD0486在复发性或难治性B细胞急性淋巴细胞白血病青少年和成人受试者中的安全性和有效性的I/II期研究

[Translation] A Phase I/II study evaluating the safety and efficacy of AZD0486 in adolescent and adult subjects with relapsed or refractory B-cell acute lymphoblastic leukemia

A部分剂量递增：评估AZD0486在16~80岁（含）Ph（+）或Ph（-）R/R B-ALL受试者中的安全性和耐受性。 B部分剂量优化：根据NCCN疗效标准评价AZD0486的初步有效性；评估AZD0486在12~80岁（含）R/R Ph（-）B-ALL受试者中的安全性和耐受性。 C部分有效性扩展：根据NCCN疗效标准评价AZD0486的有效性。

[Translation]

Part A: Dose escalation: Evaluate the safety and tolerability of AZD0486 in subjects with Ph(+) or Ph(-) R/R B-ALL aged 16-80 years (inclusive). Part B: Dose optimization: Evaluate the preliminary efficacy of AZD0486 according to NCCN efficacy criteria; Evaluate the safety and tolerability of AZD0486 in subjects with R/R Ph(-) B-ALL aged 12-80 years (inclusive). Part C: Efficacy extension: Evaluate the efficacy of AZD0486 according to NCCN efficacy criteria.

Start Date12 Oct 2024

Sponsor / Collaborator

AstraZeneca Global R&D (China) Co., Ltd.

[+2]

CTR20242703 / RecruitingPhase 3

一项在中国阵发性睡眠性血红蛋白尿症（PNH）补体抑制剂初治成人受试者中评价ravulizumab的有效性、安全性、药代动力学、药效学和免疫原性的III期、单臂、开放标签、多中心研究

[Translation] A phase III, single-arm, open-label, multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in Chinese adults with paroxysmal nocturnal hemoglobinuria (PNH) who are complement inhibitor-naive

评价ravulizumab在PNH成人受试者中的有效性

[Translation]

To evaluate the efficacy of ravulizumab in adult subjects with PNH

Start Date10 Oct 2024

Sponsor / Collaborator

AstraZeneca Global R&D (China) Co., Ltd.

[+2]

CTR20242629 / RecruitingPhase 2

一项在晚期/转移性实体瘤受试者中评价Volrustomig单药治疗或与抗肿瘤药物联合治疗的有效性和安全性的多中心、 II期临床研究：子研究-宫颈癌

[Translation] A multicenter, phase II clinical study evaluating the efficacy and safety of volrustomig as a monotherapy or in combination with anti-cancer drugs in subjects with advanced/metastatic solid tumors: Sub-study - cervical cancer

主要目的：1.通过评估确认的ORR来估计volrustomig单药治疗的有效性。2.评估volrustomig单药治疗复发/转移性宫颈癌研究受试者的安全性和耐受性。次要目的：1.通过DoR评估来估计volrustomig单药治疗的有效性。2.根据PFS评估来估计volrustomig单药治疗的有效性。3.根据TTR评估来估计volrustomig单药治疗的有效性。4.根据OS评估来估计volrustomig单药治疗的有效性。5.评估volrustomig的PK。6.研究volrustomig的免疫原性。7.通过研究者评估确认的ORR来估计volrustomig在PD-L1表达阳性和PD-L1高表达的研究受试者中的有效性。

[Translation]

Primary objectives: 1. To estimate the effectiveness of volrustomig monotherapy by evaluating the confirmed ORR. 2. To evaluate the safety and tolerability of volrustomig monotherapy in study subjects with recurrent/metastatic cervical cancer. Secondary objectives: 1. To estimate the effectiveness of volrustomig monotherapy by DoR evaluation. 2. To estimate the effectiveness of volrustomig monotherapy based on PFS evaluation. 3. To estimate the effectiveness of volrustomig monotherapy based on TTR evaluation. 4. To estimate the effectiveness of volrustomig monotherapy based on OS evaluation. 5. To evaluate the PK of volrustomig. 6. To study the immunogenicity of volrustomig. 7. To estimate the effectiveness of volrustomig in study subjects with positive PD-L1 expression and high PD-L1 expression by investigator-assessed confirmed ORR.

Start Date22 Aug 2024

Sponsor / Collaborator

AstraZeneca Global R&D (China) Co., Ltd.

[+2]

100 Clinical Results associated with AstraZeneca Global R&D (China) Co., Ltd.

0 Patents (Medical) associated with AstraZeneca Global R&D (China) Co., Ltd.

Literatures (Medical) associated with AstraZeneca Global R&D (China) Co., Ltd.

01 Feb 2022·BMJ OpenQ4 · MEDICINE

Safety and effectiveness of low-dose aspirin for the prevention of gastrointestinal cancer in adults without atherosclerotic cardiovascular disease: a population-based cohort study

Q4 · MEDICINE

ArticleOA

Author: Wan, Eric Yuk Fai ; Blais, Joseph Edgar ; Zhao, Jiaxi ; Pathadka, Swathi ; Leung, W K ; Cheung, Ka Shing ; Vora, Pareen ; Soriano-Gabarró, Montse ; Wong, Ian C K ; Shami, Jessica J P ; Chan, Esther W

ObjectiveTo assess the association between low-dose aspirin and the incidence of colorectal cancer (CRC), gastric cancer (GC), oesophageal cancer (EC) and gastrointestinal bleeding (GIB) in adults without established atherosclerotic cardiovascular disease.DesignCohort study with propensity score matching of new-users of aspirin to non-users.SettingClinical Data Analysis and Reporting System database, Hong Kong.ParticipantsAdults ≥40 years with a prescription start date of either low-dose aspirin (75–300 mg/daily) or paracetamol (non-aspirin users) between 1 January 2004 to 31 December 2008 without a history of atherosclerotic cardiovascular disease.Main outcome measuresThe primary outcome was the first diagnosis of gastrointestinal cancer (either CRC, GC or EC) and the secondary outcome was GIB. Individuals were followed from index date of prescription until the earliest occurrence of an outcome of interest, an incident diagnosis of any type of cancer besides the outcome, death or until 31 December 2017. A competing risk survival analysis was used to estimate HRs and 95% CIs with death as the competing risk.ResultsAfter matching, 49 679 aspirin and non-aspirin users were included. The median (IQR) follow-up was 10.0 (6.4) years. HRs for low-dose aspirin compared with non-aspirin users were 0.83 for CRC (95% CI, 0.76 to 0.91), 0.77 for GC (95% CI, 0.65 to 0.92) and 0.88 for EC (95% CI, 0.67 to 1.16). Patients prescribed low-dose aspirin had an increased risk of GIB (HR 1.15, 95% CI, 1.11 to 1.20), except for patients prescribed proton pump inhibitors or histamine H2-receptor antagonists (HR 1.03, 95% CI, 0.96 to 1.10).ConclusionIn this cohort study of Chinese adults, patients prescribed low-dose aspirin had reduced risks of CRC and GC and an increased risk of GIB. Among the subgroup of patients prescribed gastroprotective agents at baseline, however, the association with GIB was attenuated.

JAMA Network OpenQ1 · MEDICINE

COVID-19 Vaccination Preferences of University Students and Staff in Hong Kong

Q1 · MEDICINE

ArticleOA

Author: Wan, Eric Y. F. ; Yan, Vincent K. C. ; Fung, Lydia W. Y. ; Chan, Jacky C. H. ; Wong, Ian C. K. ; Kwan, Christine ; Cowling, Benjamin J. ; Chui, Celine S. L. ; Lai, Francisco T. T. ; Li, Silvia T. H. ; Zhao, Jiaxi ; Shami, Jessica J. P. ; Tse, Samson ; Blais, Joseph E. ; Chan, Esther W. ; Wei, Yue ; Li, Xue ; Wong, Carlos K. H.

ImportanceCOVID-19 has required universities to rapidly develop vaccination policies for students and staff, yet little is known about the preferences of these individuals toward vaccination.ObjectiveTo quantify student and staff preferences for COVID-19 vaccination at a university in Hong Kong.Design, Setting, and ParticipantsA cross-sectional online survey study was conducted from July 20 to September 21, 2021, before the announcement of a campus-wide vaccine mandate. A survey of 42 451 eligible university students and staff used discrete-choice experiment methods to quantify 7 attributes of COVID-19 vaccination: risk of a mild or moderate adverse event after vaccination, risk of a severe adverse event after vaccination, efficacy against COVID-19 infection, efficacy against severe manifestation of COVID-19 infection, duration of protection after vaccination, incentive for completing vaccination, and out-of-pocket costs.Main Outcomes and MeasuresA mixed logit regression model was used to estimate the preferences of attributes for COVID-19 vaccines and marginal willingness to pay (mWTP) adjusted for background characteristics, role, vaccination, and COVID-19 infection status of family or friends, adverse event status after vaccination among family and friends of participants, and scenario block.ResultsAmong 42 451 eligible university students and staff invited, 3423 individuals completed the survey (mean [SD] age, 27.1 [9.9] years; 2053 [60.0%] women). Participants included 2506 students (73.2%) and 917 staff (26.8%), with a response rate of 8.1%. Quarantine-free travel was preferred (β = 0.86; 95% CI, 0.72-0.99; mWTP: $235.9; 95% CI, $190.3-$294.2), followed by efficacy against any COVID-19 infection (β = 0.30; 95% CI, 0.29-0.32; mWTP: $84.1; 95% CI, $71.8-$100.8), against severe manifestation of COVID-19 infection (β = 0.25; 95% CI, 0.24-0.27; mWTP: $69.7; 95% CI, $465-$653), and risk of severe adverse events following vaccination (β = -0.24; 95% CI, -0.27 to -0.21; mWTP: -$66.8; 95% CI, -$81.5 to -$55.3). Participants were less concerned about protection duration (β = 0.17; 95% CI, 0.15-0.18; mWTP: $46.0; 95% CI, $38.6-$56.2) and risk of mild to moderate adverse events (β = -0.12; 95% CI, -0.13 to -0.10; mWTP: -$32.7; 95% CI, -$41.2 to -$26.4).Conclusions and RelevancePreference of all attributes were significant and were considered important by the participants for vaccine decision-making. Insights drawn could assist policy makers in future vaccination decisions, such as campus vaccine mandate and requirement of a third dose.

News (Medical) associated with AstraZeneca Global R&D (China) Co., Ltd.

10 Aug 2023

·endpts.com

Exclusive: AstraZeneca’s outgoing R&D chief Mene Pangalos reflects on a 14-year R&D turnaround and the industry's future

When AstraZeneca R&D executive Mene Pangalos joined the company in 2010, the UK drug giant was facing existential threats: shrinking sales , a meek pipeline and a takeover attempt by Pfizer . Pangalos saw the biggest problem: AstraZeneca’s research wasn’t delivering. AstraZeneca had a 4% success rate in bringing drugs through Phase III, trailing a 6% industry average. He pushed a new focus on quality over quantity that, from 2012 to 2016, drove AstraZeneca’s success rate to 19% — even as the industry average fell to 4%. You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Executive ChangePhase 3AcquisitionClinical Trial Failure

100 Deals associated with AstraZeneca Global R&D (China) Co., Ltd.

100 Translational Medicine associated with AstraZeneca Global R&D (China) Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 22 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

IND Approval

Phase 2 Clinical

Phase 3 Clinical

NDA/BLA

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Eculizumab ( C5 )	Atypical Hemolytic Uremic Syndrome More	Approved
Eplontersen ( TTR )	Transthyretin Amyloid Cardiomyopathy More	NDA/BLA
Capivasertib ( Akt-1 x Akt-2 x Akt-3 )	-	NDA/BLA
Reslizumab ( IL-5 )	-	NDA/BLA
Ravulizumab-CWVZ ( C5 )	-	NDA/BLA

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis